BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17507663)

  • 21. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.
    Palomero T; Odom DT; O'Neil J; Ferrando AA; Margolin A; Neuberg DS; Winter SS; Larson RS; Li W; Liu XS; Young RA; Look AT
    Blood; 2006 Aug; 108(3):986-92. PubMed ID: 16621969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia.
    dos Santos NR; Rickman DS; de Reynies A; Cormier F; Williame M; Blanchard C; Stern MH; Ghysdael J
    Blood; 2007 May; 109(9):3972-81. PubMed ID: 17192390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma.
    Sasaki E; Yatabe Y; Hashimoto M; Yamashita Y; Hasegawa Y; Kojima H; Nagasawa T; Mori N
    Pathol Int; 2007 Feb; 57(2):53-9. PubMed ID: 17300668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
    Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
    Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.
    Ferrando AA; Neuberg DS; Staunton J; Loh ML; Huard C; Raimondi SC; Behm FG; Pui CH; Downing JR; Gilliland DG; Lander ES; Golub TR; Look AT
    Cancer Cell; 2002 Feb; 1(1):75-87. PubMed ID: 12086890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice.
    O'Neil J; Billa M; Oikemus S; Kelliher M
    Oncogene; 2001 Jun; 20(29):3897-905. PubMed ID: 11439353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.
    Gerby B; Veiga DF; Krosl J; Nourreddine S; Ouellette J; Haman A; Lavoie G; Fares I; Tremblay M; Litalien V; Ottoni E; Kosic M; Geoffrion D; Ryan J; Maddox PS; Chagraoui J; Marinier A; Hébert J; Sauvageau G; Kwok BH; Roux PP; Hoang T
    J Clin Invest; 2016 Dec; 126(12):4569-4584. PubMed ID: 27797342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.
    Bruggeman SW; Hulsman D; Tanger E; Buckle T; Blom M; Zevenhoven J; van Tellingen O; van Lohuizen M
    Cancer Cell; 2007 Oct; 12(4):328-41. PubMed ID: 17936558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL.
    Ono Y; Fukuhara N; Yoshie O
    J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation.
    Chazal M; Marionnet C; Michel L; Mollier K; Dazard JE; Della Valle V; Larsen CJ; Gras MP; Basset-Séguin N
    Oncogene; 2002 Apr; 21(17):2652-61. PubMed ID: 11965538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.
    Valge-Archer VE; Osada H; Warren AJ; Forster A; Li J; Baer R; Rabbitts TH
    Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8617-21. PubMed ID: 8078932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice.
    Chiba T; Seki A; Aoki R; Ichikawa H; Negishi M; Miyagi S; Oguro H; Saraya A; Kamiya A; Nakauchi H; Yokosuka O; Iwama A
    Hepatology; 2010 Sep; 52(3):1111-23. PubMed ID: 20648475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RUNX1 is required for oncogenic
    Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
    Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SCL/TAL1: a multifaceted regulator from blood development to disease.
    Porcher C; Chagraoui H; Kristiansen MS
    Blood; 2017 Apr; 129(15):2051-2060. PubMed ID: 28179281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fit αβ T-cell receptor suppresses leukemogenesis of Pten-deficient thymocytes.
    Gon S; Loosveld M; Crouzet T; Potier D; Bonnet M; Morin SO; Michel G; Vey N; Nunès JA; Malissen B; Roncagalli R; Nadel B; Payet-Bornet D
    Haematologica; 2018 Jun; 103(6):999-1007. PubMed ID: 29567770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2.
    Obexer P; Hagenbuchner J; Rupp M; Salvador C; Holzner M; Deutsch M; Porto V; Kofler R; Unterkircher T; Ausserlechner MJ
    J Biol Chem; 2009 Nov; 284(45):30933-40. PubMed ID: 19737931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1.
    Smith KS; Chanda SK; Lingbeek M; Ross DT; Botstein D; van Lohuizen M; Cleary ML
    Mol Cell; 2003 Aug; 12(2):393-400. PubMed ID: 14536079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
    Mets E; Van der Meulen J; Van Peer G; Boice M; Mestdagh P; Van de Walle I; Lammens T; Goossens S; De Moerloose B; Benoit Y; Van Roy N; Clappier E; Poppe B; Vandesompele J; Wendel HG; Taghon T; Rondou P; Soulier J; Van Vlierberghe P; Speleman F
    Leukemia; 2015 Apr; 29(4):798-806. PubMed ID: 25231743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.
    Ausserlechner MJ; Obexer P; Geley S; Kofler R
    Leukemia; 2005 Jun; 19(6):1051-7. PubMed ID: 15800668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes.
    Breit TM; Mol EJ; Wolvers-Tettero IL; Ludwig WD; van Wering ER; van Dongen JJ
    J Exp Med; 1993 Apr; 177(4):965-77. PubMed ID: 8459224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.